Transgene,a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, has recently announced theappointment of Lucie Larguier as Chief Financial Officer.
Formerly the VP of Corporate Communication and Investor relations, in her new role as CFO Lucie will be responsible for all aspects of the Company's financial strategy, management and operations to ensure efficient delivery of Transgene's immunotherapy pipeline.
Lucie succeeds Arnaud Dubarry, who has stepped down to pursue other opportunities.
Already a member of the executive management committee, Ms Larguier brings a comprehensive, cross-functional view of the company's operations and finances, as well as a deep knowledge of Transgene's investor base.
Since 2016, Lucie has served as the Director of Corporate Communications and Investor Relations, reporting directly to the CEO. Lucie contributed significantly to strengthening the external visibility of Transgene.
Prior to joining Transgene, Lucie spent more than 10 years in the consultancty environment, advising companies on their corporate and financial messages.
Alongside this novel appointment, Transgene has promoted Christelle Schwoerer to Chief Human Resources Officer. Schwoerer joined Transgene's Human Resources department in 2013, and her knowledge of the organisation and its culture are real assets in her new role.
Alessandro Riva, MD, Chair and CEO of Transgene, commented: “Having worked extensively with Lucie since taking on the role of CEO, I am convinced that her knowledge and experience make her an excellent fit as CFO at Transgene. She identifies closely with the culture we are building, has made significant contributions to the success of the company to date and is well placed to support our ambitious plans to accelerate our pipeline of highly promising cancer immunotherapies.”
